Larotrectinib treatment scope and price

Larotrectinib is a new type of targeted therapy used to treat some rare but serious types of cancer. Its mechanism of action is to target tumors carrying NTRK gene fusions, which are found in a variety of cancer types, including but not limited to infantile fibrosarcoma, adult soft tissue sarcoma, thyroid cancer, and pancreatic cancer. Larotrectinib can effectively inhibit the growth of these tumors, providing patients with a new treatment option.

In the domestic market, larotrectinib is already on the market, but it has not yet been included in medical insurance. Since it has not been on the market for a long time in China, it may be difficult to purchase it in hospitals. For specific circumstances, it is recommended to consult the local hospital pharmacy for more information.

In foreign markets, larotrectinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions, and the price is around two to three thousand. It should be noted that despite the price difference, the ingredients of original drugs and generic drugs are basically the same, so you can make a trade-off based on your personal financial situation when choosing.

The launch of larotrectinib provides new hope for some rare cancer patients, but it also faces the challenge of high price. For patients and their families, in addition to paying attention to the efficacy, they must also consider their financial affordability and find the treatment plan that best suits them. At the same time, governments and medical institutions should also consider how to include such new drugs in medical insurance to ensure that more patients can benefit.